CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
CME Dinner Meetings Telewebs Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2005-02-03): Type 1 interferon augments murine response to DNA-based anti-HCV vaccine

Science

Type 1 interferon augments murine response to DNA-based anti-HCV vaccine

Last Updated: 2005-02-03 16:49:41 -0400 (Reuters Health)

NEW YORK (Reuters Health) - Mice treated with type 1 interferon have enhanced responses to DNA vaccination against hepatitis C virus core protein, according to a report in the February issue of the Journal of Medical Virology.

At Brown Medical School in Providence, Rhode Island, Dr. Stephan Gehring and colleagues treated mice with two types of recombinant type 1 interferon proteins: hybrid interferon alpha A/D (also referred to as universal type 1 interferon), and human pegylated interferon alpha-2a. In addition, the researchers tested the effect of administration of a plasmid expressing murine interferon-alpha.

According to the article, analysis of conventional cytotoxic T lymphocyte assays and an in vivo tumor challenge model showed that low doses of hybrid interferon alpha A/D and pegylated interferon "augmented three to fourfold the cellular immune response to DNA-based vaccination."

"Importantly," the investigators add, "augmentation occurred within a narrow concentration range." Whereas low doses of both of these types of interferon induced strong augmentation of vaccination, increasing the doses resulted in significantly decreased augmentation.

Administration of the plasmid expressing murine interferon-alpha "strongly suppressed the specific cytotoxic T lymphocyte activity" of the vaccine, the researchers report.

These findings, they conclude, "demonstrate that the immunomodulatory properties of interferon-alpha can be exploited to augment DNA based immunization, but it is important to consider the effects of dose on both cellular and humoral immune response for optimal augmentation."

J Med Virol 2005;75:249-257

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
CME Dinner Meeting
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.